PEN

Penumbra, Inc.
$328.69
+0.80 (+0.24%)
Mkt Cap 12.93B
Volume 426,496
52W Range 221.26-362.41
Sector Healthcare
Beta 0.73
EPS (TTM) 4.38
P/E Ratio 75.04
Revenue (TTM) 1.45B
Rev Growth (5Y) +20.2%
EPS Growth (5Y) +28.2%
AlphaVal · Fair Value
$243.94
Overvalued · Moderate
34.7% above fair value
AlphaQuality · Grade
B-
Platform & Compounding FCF
65.4 / 100 composite

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 1.40B 1.19B 1.06B 847.13M 747.59M 560.41M 547.40M 444.94M 333.76M 263.32M 186.09M 125.51M
Net Income 177.69M 14.01M 90.95M (2.00M) 5.28M (15.70M) 48.46M 6.60M 4.66M 14.81M 2.37M 2.25M
EPS 4.57 0.36 2.37 -0.05 0.14 -0.54 1.39 0.18 0.14 0.49 0.09 -0.03
Free Cash Flow 174.93M 147.30M 82.12M (74.96M) (11.68M) (58.00M) 4.54M 19.20M (2.34M) (26.44M) N/A N/A
FCF / Share 4.49 3.81 2.14 -1.98 -0.32 -1.62 0.13 0.53 -0.07 -0.87 N/A N/A
Operating CF 238.66M 168.48M 97.33M (55.66M) 9.50M (33.24M) 26.65M 28.81M 12.69M (12.81M) N/A N/A
Total Assets 1.83B 1.53B 1.56B 1.37B 1.24B 822.98M 665.90M 515.01M 476.67M 308.25M N/A N/A
Total Debt 219.70M 223.39M 234.34M 235.77M 173.55M 77.28M 82.30M 0 0 0 N/A N/A
Cash & Equiv 186.90M 324.40M 167.49M 69.86M 59.38M 69.67M 72.78M 67.85M 50.64M 13.24M N/A N/A
Book Value 1.43B 1.15B 1.18B 998.86M 953.93M 641.50M 485.89M 422.24M 400.41M 266.55M N/A N/A
Return on Equity 0.12 0.01 0.08 -0.00 0.01 -0.02 0.10 0.02 0.01 0.06 N/A N/A
PEN News
Artisan Small Cap Fund Q1 2026 Portfolio Activity
May 07, 2026 05:15 AM · seekingalpha.com
Penumbra (PEN) Misses Q1 Earnings Estimates
May 06, 2026 02:25 PM · zacks.com
Penumbra, Inc. Reports First Quarter 2026 Financial Results
May 06, 2026 12:05 PM · prnewswire.com
ALC vs. PEN: Which Stock Should Value Investors Buy Now?
May 05, 2026 08:41 AM · zacks.com
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock
Apr 27, 2026 09:45 AM · zacks.com
Here's Why Penumbra (PEN) is a Strong Growth Stock
Apr 15, 2026 06:45 AM · zacks.com
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
Apr 13, 2026 05:00 AM · prnewswire.com
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
Apr 10, 2026 09:45 AM · zacks.com
Are OMEX, PEN, SNCY, CWAN Obtaining Fair Deals for their Shareholders?
Apr 10, 2026 09:41 AM · prnewswire.com
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Apr 07, 2026 06:04 PM · businesswire.com